Gilead Sciences (GILD) Prepaid Assets (2009 - 2026)
Gilead Sciences' (GILD) quarterly Prepaid Assets came in at $3.8 billion in Q2 2026, up 29.67% on a YoY basis from $2.9 billion in Q2 2025, and down 13.43% quarter-over-quarter from $4.3 billion in Q1 2026.
Analysis
Gilead Sciences (GILD) Prepaid Assets (2009 - 2026) Analysis & Trends
Gilead Sciences (GILD) has reported Prepaid Assets for 18 consecutive years, with $3.8 billion the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Prepaid Assets rose 29.67% year-over-year to $3.8 billion; the trailing twelve-month figure through Jun 2026 stood at $3.8 billion (up 29.67% YoY), and the FY2025 full-year result was $4.0 billion, up 31.85% from the prior year.
- Prepaid Assets fell to $3.8 billion in Q2 2026 per GILD's latest filing, from $4.3 billion in the prior quarter.
- Across five years, Prepaid Assets topped out at $4.3 billion in Q1 2026 and bottomed at $1.8 billion in Q2 2023.
- Historically, Prepaid Assets has averaged $2.8 billion across 5 years, with a median of $2.8 billion in 2024.
- The sharpest annual moves came in 2022 and 2024: Prepaid Assets retreated 17.14% in 2022, then jumped 62.55% in 2024.
- Over 5 years, Prepaid Assets stood at $1.8 billion in 2022, then surged by 33.82% to $2.4 billion in 2023, then gained by 28.56% to $3.1 billion in 2024, then surged by 31.85% to $4.0 billion in 2025, then slipped by 6.59% to $3.8 billion in 2026.
- According to Business Quant data, Prepaid Assets over the past three periods registered $3.8 billion, $4.3 billion, and $4.0 billion for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn |
| 10 | Insmed | 27.67 Bn | 26.51 Bn | 358.27 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 3.76 Bn |
| Mar 31, 2026 | 4.34 Bn |
| Dec 31, 2025 | 4.02 Bn |
| Sep 30, 2025 | 3.65 Bn |
| Jun 30, 2025 | 2.90 Bn |
| Mar 31, 2025 | 2.83 Bn |
| Dec 31, 2024 | 3.05 Bn |
| Sep 30, 2024 | 3.29 Bn |
| Jun 30, 2024 | 2.86 Bn |
| Mar 31, 2024 | 2.80 Bn |
| Dec 31, 2023 | 2.37 Bn |
| Sep 30, 2023 | 2.66 Bn |
| Jun 30, 2023 | 1.76 Bn |
| Mar 31, 2023 | 1.85 Bn |
| Dec 31, 2022 | 1.77 Bn |
| Sep 30, 2022 | 2.08 Bn |
| Jun 30, 2022 | 1.90 Bn |
| Mar 31, 2022 | 2.04 Bn |
| Dec 31, 2021 | 2.14 Bn |
| Sep 30, 2021 | 2.01 Bn |